Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China

Objective: The aim of this study is to evaluate the safety of cephalosporins, based on utilization and adverse drug events (ADEs). Methods: This is a retrospective study using data on cephalosporins, obtained from Yangtze River hospital drug information and the Wuhan adverse drug reactions monitoring center database, from January 2009 to December 2010, in 30 hospitals in China. Results: 22/44 (55%) cephalosporins were third-generation, which accounted for more than 50% of total expenditure. The top five cephalosporins (sorted by their defined daily doses) were cefodizime sodium, cefoperazone/sulbactam sodium, cefaclor, cefixime and cefmenoxime hydrochloride, which were used 182.93, 110.63, 109.09, 101.47 and 100.05 defined daily dose per 10,000 days, respectively. Third-generation cephalosporins were responsible for 747/1337 ADEs (55.87%). In particular, 208 episodes (15.56%) were associated with ceftriaxone. The most frequently reported damages were involved in the skin and its appendages (967, 68.92%). 603 (45.10%) were identified as definite in causality evaluation. Cefaclor was found to be safer than other cephalosporins, whereas ceftriaxone was found to be less safe. Conclusion: This retrospective evaluation demonstrated that overused and misused cephalosporins caused a relatively high incidence of ADEs. Therefore, surveillance should be strengthened successfully to optimize the rational use of cephalosporins.

[1]  L. Ji-guang.  Application analysis of antibiotics in our hospital , 2013 .

[2]  B. Hayes,et al.  The use of cephalosporins in penicillin-allergic patients: a literature review. , 2012, The Journal of emergency medicine.

[3]  K. Mühlemann,et al.  Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe. , 2011, The Journal of hospital infection.

[4]  Boris Sobolev,et al.  Outcomes of emergency department patients presenting with adverse drug events. , 2011, Annals of emergency medicine.

[5]  E. Denamur,et al.  Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  Wei Zhang,et al.  Patient Knowledge and Antibiotic Abuse: Evidence from an Audit Study in China , 2010, Journal of health economics.

[7]  R. Isturiz.  Optimizing antimicrobial prescribing. , 2010, International journal of antimicrobial agents.

[8]  T. Welte,et al.  Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. , 2010, International journal of antimicrobial agents.

[9]  Shixia Wang,et al.  Clostridium difficile infections in China , 2010, Journal of biomedical research.

[10]  W. Xiuying,et al.  Relationship of Antibacterials Use and Bacterial Drug Resistance in Hospitalized Patients , 2010 .

[11]  Hu Ning-yan.  Use of Antibiotics in Shanghai Second and Third Level Hospitals During the Period of 2007-2008 , 2010 .

[12]  Jia Hui-jun.  Application analysis of antibiotics in our hospital in 2009 , 2010 .

[13]  Zeng Xiao-dan.  Analysis of 612 Cases of Antibiotics-induced ADR in Our Hospital , 2010 .

[14]  M. Doherty.  Algorithms for assessing the probability of an Adverse Drug Reaction , 2009 .

[15]  B. Zink.  Learning from our history. , 2008, Journal of Emergency Medicine.

[16]  R. Owens.  Antimicrobial stewardship: concepts and strategies in the 21st century. , 2008, Diagnostic microbiology and infectious disease.

[17]  R. Owens,et al.  Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. , 2007, Diagnostic microbiology and infectious disease.

[18]  J. Rotschafer,et al.  Adverse events associated with the use of oral cephalosporins/cephems. , 2007, Diagnostic microbiology and infectious disease.

[19]  M. Lapeyre-Mestre,et al.  Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. , 2006, Joint, bone, spine : revue du rhumatisme.

[20]  E. Pérez-Inestrosa,et al.  Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. , 2006, The Journal of allergy and clinical immunology.

[21]  M. Hartmann,et al.  Antibiotic use in German university hospitals 1998-2000 (Project INTERUNI-II). , 2004, International journal of antimicrobial agents.

[22]  I. Kobayashi,et al.  Antimicrobial resistance of Neisseria gonorrhoeae in Japan, 1993-2002: continuous increasing of ciprofloxacin-resistant isolates. , 2004, International journal of antimicrobial agents.

[23]  Thomas Bieber,et al.  Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. , 2004, The Journal of allergy and clinical immunology.

[24]  Saban Eren,et al.  Rational antibiotic use and academic staff. , 2003, International journal of antimicrobial agents.

[25]  Anne E. Trontell,et al.  How the US Food and Drug Administration Defines and Detects Adverse Drug Events , 2001 .

[26]  Victor L. Yu,et al.  Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.

[27]  B. Meyers.  Cefaclor revisited. , 2000, Clinical Therapeutics.

[28]  C. Sabella,et al.  Principles of selection and use of antimicrobial agents , 1999 .

[29]  E. Bingen.  [The new cephalosporins]. , 1996, Archives de pédiatrie.

[30]  W. Craig.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.